The aberrant overexpression of Lysine-specific demethylase 1 (LSD1/KDM1A) is a common feature across a wide spectrum of human cancers, and its elevated levels correlate with poor survival of cancer patients, making it an attractive target for pharmacological intervention. However, the clinical trials of LSD1 small-molecule inhibitors are facing few serious challenges, including toxicity at therapeutic doses. Here, the authors reported the discovery of LD-110 as a potent PROTAC degrader via the ubiquitin-proteasome system, leading to significantly growth suppression of cancer cells both in vitro and in vivo.

Researchers have developed an ultra-mild bisulfite sequencing method (UMBS-seq) that preserves DNA integrity while delivering highly accurate methylation measurements. The new approach overcomes long-standing limitations of traditional bisulfite and enzymatic methods, enabling more reliable detection of cancer-related epigenetic signals. The technology, published in Nature Communications and licensed to Ellis Bio, could improve liquid biopsy testing and accelerate development of methylation-based diagnostics.

Although cancer incidence rises with age, the very old seem to be at less risk. A study led by Stanford University shows this phenomenon in mice and explores the protective effect of advanced age.

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see their cancer return sooner.

Published in Blood Advances, the research is the first longitudinal, single-cell, multi-omic study of cilta-cel in multiple myeloma. Cilta-cel (ciltacabtagene autoleucel) is a type of CAR T cell therapy used to treat relapsed or refractory multiple myeloma. It works by using a patient's own T cells, which are genetically engineered in a lab to target and kill cancer cells that have B cell maturation antigen (BCMA) on their surface. The modified T cells are then infused back into the patient as a one-time treatment to fight the cancer.